» Articles » PMID: 29160621

Magnetic Resonance Imaging in Heart Failure, Including Coronary Imaging: Numbers, Facts, and Challenges

Overview
Journal ESC Heart Fail
Date 2017 Nov 22
PMID 29160621
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Coronary artery disease (CAD) is a major risk factor for the incidence and progression of heart failure (HF). HF is characterized by a substantial morbidity and mortality and its lifetime risk is estimated at approximately 20% for men and women. As patients are in most cases identified only after developing overt clinical symptoms, detecting early stages of CAD and HF is of paramount importance. Due to its non-invasiveness, excellent soft-tissue contrast, high spatial resolution, and multiparametric nature, cardiovascular magnetic resonance (CMR) imaging has emerged as a promising radiation-free technique to assess a wide range of cardiovascular diseases such as CAD or HF, enabling a comprehensive evaluation of myocardial anatomy, regional and global function, and viability with the additional benefit of in vivo tissue characterization. CMR has the potential to enhance our understanding of coronary atherosclerosis and the aetiology of HF on functional and biological levels, to identify patients at risk for CAD or HF, and to enable individualized patient management and improved outcomes. Even though larger-scale studies on the different applications of CMR for the assessment of heart failure are scarce, recent research highlighted new possible clinical applications for CMR in the evaluation of CAD and HF.

Citing Articles

Evaluation of left ventricular function in patients with acute ischaemic stroke using cine cardiovascular magnetic resonance imaging.

Hellwig S, Grittner U, Elgeti M, Wyschkon S, Nagel S, Fiebach J ESC Heart Fail. 2020; 7(5):2572-2580.

PMID: 32667736 PMC: 7524103. DOI: 10.1002/ehf2.12833.


The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians.

Anker M, Bouleti C, Christodoulides T, Durante A, Gara E, Hadzibegovic S ESC Heart Fail. 2020; 7(3):873-877.

PMID: 32352242 PMC: 7261537. DOI: 10.1002/ehf2.12674.


Magnetic resonance imaging in heart failure, including coronary imaging: numbers, facts, and challenges.

Adams L, Noutsias M, Bigalke B, Makowski M ESC Heart Fail. 2017; 5(1):3-8.

PMID: 29160621 PMC: 5793958. DOI: 10.1002/ehf2.12236.

References
1.
Rommel K, von Roeder M, Latuscynski K, Oberueck C, Blazek S, Fengler K . Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2016; 67(15):1815-1825. DOI: 10.1016/j.jacc.2016.02.018. View

2.
Mozaffarian D, Benjamin E, Go A, Arnett D, Blaha M, Cushman M . Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2015; 133(4):e38-360. DOI: 10.1161/CIR.0000000000000350. View

3.
Lota A, Gatehouse P, Mohiaddin R . T2 mapping and T2* imaging in heart failure. Heart Fail Rev. 2017; 22(4):431-440. PMC: 5487811. DOI: 10.1007/s10741-017-9616-5. View

4.
Spuentrup E, Botnar R, Wiethoff A, Ibrahim T, Kelle S, Katoh M . MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol. 2008; 18(9):1995-2005. DOI: 10.1007/s00330-008-0965-2. View

5.
Kempny A, Fernandez-Jimenez R, Orwat S, Schuler P, Bunck A, Maintz D . Quantification of biventricular myocardial function using cardiac magnetic resonance feature tracking, endocardial border delineation and echocardiographic speckle tracking in patients with repaired tetralogy of Fallot and healthy controls. J Cardiovasc Magn Reson. 2012; 14:32. PMC: 3464868. DOI: 10.1186/1532-429X-14-32. View